Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

<p>Supplementary Table S1: Genomic and clinical characteristics of the study cohort.</p>

Պահպանված է:

Մատենագիտական մանրամասներ
Հիմնական հեղինակ:	Ryan D. Chow (15109654) (author)
Այլ հեղինակներ:	Tai Michaels (15122331) (author), Stefania Bellone (15122334) (author), Tobias M.P. Hartwich (15122337) (author), Elena Bonazzoli (15122340) (author), Akiko Iwasaki (15122343) (author), Eric Song (15122346) (author), Alessandro D. Santin (15122349) (author)
Հրապարակվել է:	2025
Խորագրեր:	Cancer Therapeutic Research and Development Immuno-oncology Gynecological Cancers Endometrial cancer Immunotherapy Translational Research
Ցուցիչներ:	Ավելացրեք ցուցիչ Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!

Նմանատիպ նյութեր

Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
‌: Ryan D. Chow (15109654)
Հրապարակվել է: (2025)

Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
‌: Ryan D. Chow (15109654)
Հրապարակվել է: (2025)

Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
‌: Ryan D. Chow (15109654)
Հրապարակվել է: (2025)

Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
‌: Zannel Blanchard (16617018)
Հրապարակվել է: (2025)

Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
‌: Zannel Blanchard (16617018)
Հրապարակվել է: (2025)

Supplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
‌: Zannel Blanchard (16617018)
Հրապարակվել է: (2025)

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
‌: Niccolò G. Santin (22229756)
Հրապարակվել է: (2025)

Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
‌: Niccolò G. Santin (22229756)
Հրապարակվել է: (2025)

Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
‌: Niccolò G. Santin (22229756)
Հրապարակվել է: (2025)

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
‌: Niccolò G. Santin (22229756)
Հրապարակվել է: (2025)

Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
‌: Niccolò G. Santin (22229756)
Հրապարակվել է: (2025)

Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
‌: Niccolò G. Santin (22229756)
Հրապարակվել է: (2025)

Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
‌: Niccolò G. Santin (22229756)
Հրապարակվել է: (2025)

Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
‌: Niccolò G. Santin (22229756)
Հրապարակվել է: (2025)

Table 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
‌: Yumeng Cai (5591276)
Հրապարակվել է: (2025)

Table 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
‌: Yumeng Cai (5591276)
Հրապարակվել է: (2025)

Image 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
‌: Yumeng Cai (5591276)
Հրապարակվել է: (2025)

Table 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.docx
‌: Yumeng Cai (5591276)
Հրապարակվել է: (2025)

Image 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
‌: Yumeng Cai (5591276)
Հրապարակվել է: (2025)

Image 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
‌: Yumeng Cai (5591276)
Հրապարակվել է: (2025)

Image 5_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.jpg
‌: Yumeng Cai (5591276)
Հրապարակվել է: (2025)

Image 4_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
‌: Yumeng Cai (5591276)
Հրապարակվել է: (2025)

Image 6_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
‌: Yumeng Cai (5591276)
Հրապարակվել է: (2025)

Image 7_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tiff
‌: Yumeng Cai (5591276)
Հրապարակվել է: (2025)

Table 1_Evaluation of microsatellite instability patterns in mismatch repair deficiency: a retrospective analysis of 285 endometrial cancers.docx
‌: Cheng Wang (102692)
Հրապարակվել է: (2025)

Supplementary Figure 1 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
‌: Shigehiro Yagishita (15088446)
Հրապարակվել է: (2025)

Supplementary Figure 2 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
‌: Shigehiro Yagishita (15088446)
Հրապարակվել է: (2025)

Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
‌: Shigehiro Yagishita (15088446)
Հրապարակվել է: (2025)

Supplementary Figure 4 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
‌: Shigehiro Yagishita (15088446)
Հրապարակվել է: (2025)

Supplementary Table S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
‌: Arnaud Da Cruz Paula (17316230)
Հրապարակվել է: (2025)

Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis
‌: Yi Tang (55726)
Հրապարակվել է: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
‌: Martina S.J. McDermott (15206951)
Հրապարակվել է: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
‌: Martina S.J. McDermott (15206951)
Հրապարակվել է: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
‌: Martina S.J. McDermott (15206951)
Հրապարակվել է: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
‌: Martina S.J. McDermott (15206951)
Հրապարակվել է: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
‌: Martina S.J. McDermott (15206951)
Հրապարակվել է: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
‌: Martina S.J. McDermott (15206951)
Հրապարակվել է: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
‌: Martina S.J. McDermott (15206951)
Հրապարակվել է: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
‌: Martina S.J. McDermott (15206951)
Հրապարակվել է: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
‌: Martina S.J. McDermott (15206951)
Հրապարակվել է: (2025)